AB267. Association of genetic polymorphism of CCNE1 and RIP2 with bladder cancer risk

Background: A single nucleotide polymorphism is identified at CCNE1 and RIP2. We evaluated the relationship between the CCNE1 or RIP2 and the risk, clinic stage and pathologic grade of bladder cancer.

Methods: Peripheral venous blood samples were obtained from 176 patients with bladder cancer and 210 controls with no cancers of any kinds. The diagnoses, pathological stage of bladder cancer were all determined according to the pathological reports of transurethral bladder cancer resection and radical cystectomy. The polymorphism was determined by polymerase chain reaction and sequencing methods.

Results: (I) The distribution of the CCNE1 and RIP 2 allele frequencies among control subjects was in Hardy-Weinberg equilibrium; (II) the frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (40.91%) than in controls (30.95%) (P<0.05, OR=1.54, 95% CI 1.02–2.45). The frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (72.73%) than in controls (62.38%) (P<0.05, OR=1.61, 95% CI, 1.04–2.48); (III) there was no association between the CCNE1 (rs8102137) and RIP2 (rs42490). Polymorphisms and Pathological grade and clinical stage of bladder cancer.

Conclusions: The CCNE1 (rs8102137) and RIP2 (rs42490) polymorphism have interaction in occurrence of bladder cancer process, no association with Pathological grade and clinical stage of bladder cancer.

Keywords: Bladder cancer; genetic polymorphism; CCNE1; RIP2